Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer

TitleCharacterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer
Publication TypeMiscellaneous
Year of Publication2015
AuthorsSmall, EJay, Huang, J, Youngren, J, Sokolov, A, Aggarwal, RRaj, Thomas, G, True, LD, Zhang, L, Foye, A, Alumkal, JJ, ,